Bao Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bao Li has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Bin Yang
Department of Cardiology, the Second Hospital of Shanxi Medical University, Taiyuan, China
4 shared publications Luo Lv
Department of Cardiology, The First Hospital of Shanxi Medical University, School of Medicine, Shanxi Medical University, Taiyuan, China
4 shared publicationsBin Yang
Second Hospital of Shanxi Medical University, Taiyuan, China
3 shared publicationsBomeng Zhao
Department of Respiratory and Critical Care Medicine, The Second Hospital of Shanxi Medical University, School of Medicine, Shanxi Medical University, Taiyuan, China
3 shared publicationsChun-Ling Guo
Department of Cardiology, the Second Hospital of Shanxi Medical University, Taiyuan, China
3 shared publications- Xiao-Lin Wang
Department of Pediatrics, Heping Hospital and Institute of cardiovascular disease, Changzhi Medical College, Changzhi, China
3 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
The synergistic pattern of metabolic-inflammatory changes jointly predicts cardiovascular risk in Chinese middle-aged and older adults: a prospective cohort study
The interplay between metabolic dysregulation and chronic inflammation is pivotal in the development of cardiovascular disease. However, the joint prognostic value of their dynamic trajectories remains unclear. Current risk assessment predominantly relies on single-timepoint, static measurements, which fail to capture their temporal evolution and synergistic interactions. This study aimed to investigate the synergistic pattern derived from the dynamic trajectories of metabolism and inflammation for predicting major adverse cardiovascular events(MACE). This prospective cohort study included 4,968 Chinese middle-aged and older adults free of baseline cardiovascular disease from the China Health and Retirement Longitudinal Study (CHARLS). The triglyceride-glucose-body mass index and high-sensitivity C-reactive protein were used to define metabolic and inflammatory status, respectively. Based on measurements at two time points, participants were classified as being at “high risk” if they exhibited sustained high levels or a transition from low to high in either metabolic or inflammatory status. By cross-classifying metabolic and inflammatory high-risk status, four mutually exclusive synergistic patterns were derived: low-low (reference), high-high, metabolism-dominant (high metabolic risk only), and inflammation-dominant (high inflammatory risk only). The primary outcome was incident MACE (a composite of cardiovascular death and self-reported physician-diagnosed heart attack, coronary heart disease, angina, congestive heart failure, other heart problems, or stroke). Cox proportional hazards models were used to calculate hazard ratios for each pattern compared with the low-low group. The incremental predictive value was assessed using the C-statistic, net reclassification improvement, and integrated discrimination improvement. Subgroup and sensitivity analyses were performed. Over a median follow-up of 5.25 years, 1,087 MACE events were documented. Compared with the low-low group, the metabolism-dominant group exhibited the highest risk of MACE (fully adjusted HR = 1.39, 95% CI: 1.15–1.68, p < 0.001), followed by the high-high group (HR = 1.31, 95% CI: 1.10–1.57, p = 0.002). The inflammation-dominant group was not significantly associated with MACE risk (HR = 1.15, 95% CI: 0.95–1.39, p = 0.146). In subgroup analyses, the association for the high-high pattern appeared stronger in participants aged < 60 years (HR = 1.54, 95% CI:1.16–2.05) compared with those aged ≥ 60 years (HR = 1.23, 95% CI: 0.91–1.66), although no significant interaction was detected (P for interaction = 0.204). Adding the synergistic patterns to a model containing traditional risk factors yielded a modest but significant improvement in risk prediction (ΔC-index = 0.006, P = 0.0465; NRI = 0.079, P = 0.031; IDI = 0.0024, P = 0.045). Sensitivity analyses using a stricter definition of high inflammatory status (≥ 75th percentile per wave) confirmed the robustness of the findings (HR for high-high = 1.33, 95% CI: 1.10–1.61, p = 0.003). This study demonstrates that the joint patterns of metabolic and inflammatory changes—defined using two repeated measurements—provide independent prognostic information for cardiovascular events beyond traditional risk factors. Among the four synergistic patterns identified, the metabolism-dominant group exhibited the highest MACE risk, suggesting that, within this cohort and under our measurement framework, metabolic dysregulation may be a more prominent predictor of cardiovascular risk than inflammation alone. The lack of significant association for the inflammation-dominant pattern alone may indicate that low-grade inflammation confers excess risk primarily when accompanied by adverse metabolic status; however, this interpretation should be made cautiously given potential assay-related heterogeneity and limited power for some contrasts.
- 17 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessThe synergistic pattern of metabolic-inflammatory changes jointly predicts cardiovascular risk in Chinese middle-aged and older adults: a prospective cohort study
The interplay between metabolic dysregulation and chronic inflammation is pivotal in the development of cardiovascular disease. However, the joint prognostic value of their dynamic trajectories remains unclear. Current risk assessment predominantly relies on single-timepoint, static measurements, which fail to capture their temporal evolution and synergistic interactions. This study aimed to investigate the synergistic pattern derived from the dynamic trajectories of metabolism and inflammation for predicting major adverse cardiovascular events(MACE). This prospective cohort study included 4,968 Chinese middle-aged and older adults free of baseline cardiovascular disease from the China Health and Retirement Longitudinal Study (CHARLS). The triglyceride-glucose-body mass index and high-sensitivity C-reactive protein were used to define metabolic and inflammatory status, respectively. Based on measurements at two time points, participants were classified as being at “high risk” if they exhibited sustained high levels or a transition from low to high in either metabolic or inflammatory status. By cross-classifying metabolic and inflammatory high-risk status, four mutually exclusive synergistic patterns were derived: low-low (reference), high-high, metabolism-dominant (high metabolic risk only), and inflammation-dominant (high inflammatory risk only). The primary outcome was incident MACE (a composite of cardiovascular death and self-reported physician-diagnosed heart attack, coronary heart disease, angina, congestive heart failure, other heart problems, or stroke). Cox proportional hazards models were used to calculate hazard ratios for each pattern compared with the low-low group. The incremental predictive value was assessed using the C-statistic, net reclassification improvement, and integrated discrimination improvement. Subgroup and sensitivity analyses were performed. Over a median follow-up of 5.25 years, 1,087 MACE events were documented. Compared with the low-low group, the metabolism-dominant group exhibited the highest risk of MACE (fully adjusted HR = 1.39, 95% CI: 1.15–1.68, p < 0.001), followed by the high-high group (HR = 1.31, 95% CI: 1.10–1.57, p = 0.002). The inflammation-dominant group was not significantly associated with MACE risk (HR = 1.15, 95% CI: 0.95–1.39, p = 0.146). In subgroup analyses, the association for the high-high pattern appeared stronger in participants aged < 60 years (HR = 1.54, 95% CI:1.16–2.05) compared with those aged ≥ 60 years (HR = 1.23, 95% CI: 0.91–1.66), although no significant interaction was detected (P for interaction = 0.204). Adding the synergistic patterns to a model containing traditional risk factors yielded a modest but significant improvement in risk prediction (ΔC-index = 0.006, P = 0.0465; NRI = 0.079, P = 0.031; IDI = 0.0024, P = 0.045). Sensitivity analyses using a stricter definition of high inflammatory status (≥ 75th percentile per wave) confirmed the robustness of the findings (HR for high-high = 1.33, 95% CI: 1.10–1.61, p = 0.003). This study demonstrates that the joint patterns of metabolic and inflammatory changes—defined using two repeated measurements—provide independent prognostic information for cardiovascular events beyond traditional risk factors. Among the four synergistic patterns identified, the metabolism-dominant group exhibited the highest MACE risk, suggesting that, within this cohort and under our measurement framework, metabolic dysregulation may be a more prominent predictor of cardiovascular risk than inflammation alone. The lack of significant association for the inflammation-dominant pattern alone may indicate that low-grade inflammation confers excess risk primarily when accompanied by adverse metabolic status; however, this interpretation should be made cautiously given potential assay-related heterogeneity and limited power for some contrasts.
- Open Access
- 25 January 2026
- Published by Springer Nature in EJNMMI Research
- Vol. 16 (1)
Quantitative assessment of graves’ ophthalmopathy activity using 99mTc-DTPA SPECT/CT orbital imaging: a feasibility study with multiple indicators
Graves' ophthalmopathy (GO) is a challenging autoimmune manifestation of Graves' disease, whose management relies on accurate assessment of inflamm
- 25 January 2026
- Published by Springer Nature in EJNMMI Research
- Vol. 16 (1)
Open AccessQuantitative assessment of graves’ ophthalmopathy activity using 99mTc-DTPA SPECT/CT orbital imaging: a feasibility study with multiple indicators
Graves' ophthalmopathy (GO) is a challenging autoimmune manifestation of Graves' disease, whose management relies on accurate assessment of inflamm
- Open Access
- 7 January 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1700630
Global research trends on exosomes in atherosclerosis: a bibliometric and scientometric analysis (2004–2025)
Background: Exosomes play multifaceted roles in atherosclerosis, contributing to vascular inflammation, immune regulation, and tissue repair. This duality has drawn attention to their potential clinical utility, both as diagnostic indicators and as novel therapeutic avenues. However, despite the rapid expansion of research, a comprehensive scientometric overview of this field remains lacking. Methods: From 2004 to July 29, 2025, publications related to exosomes and atherosclerosis were screened in the Web of Science Core Collection (WoSCC) and Scopus. After deduplication, 1,179 records (964 articles, 215 reviews) were included. Bibliometric analyses were conducted using CiteSpace, VOSviewer, and the bibliometrix R package. Indicators examined included publication trends, global distribution, institutional and author contributions, co-citation patterns, and keyword evolution. Results: Publications on exosomes in atherosclerosis have risen sharply since 2015, consistent with Price's Law. China contributes the largest volume, while the United States shows stronger international collaboration. Central South University, Capital Medical University, and Harvard University rank among the most productive institutions. Key contributors include Elena Aikawa and Lijun Yuan. Major publication venues are the International Journal of Molecular Sciences, Frontiers in Cardiovascular Medicine, and Frontiers in Immunology. Keyword and co-citation mapping revealed three major research axes: RNA-mediated regulation, immune and endothelial interactions, and emerging translational applications such as engineered exosomes and diagnostic biomarkers. Conclusion: This bibliometric analysis characterizes global research development and shows a shift from descriptive studies toward mechanistic insight and translational innovation. These trends may facilitate future efforts in biomarker discovery, standardized exosome workflows, and therapeutic development.
- 7 January 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1700630
Open AccessGlobal research trends on exosomes in atherosclerosis: a bibliometric and scientometric analysis (2004–2025)
Background: Exosomes play multifaceted roles in atherosclerosis, contributing to vascular inflammation, immune regulation, and tissue repair. This duality has drawn attention to their potential clinical utility, both as diagnostic indicators and as novel therapeutic avenues. However, despite the rapid expansion of research, a comprehensive scientometric overview of this field remains lacking. Methods: From 2004 to July 29, 2025, publications related to exosomes and atherosclerosis were screened in the Web of Science Core Collection (WoSCC) and Scopus. After deduplication, 1,179 records (964 articles, 215 reviews) were included. Bibliometric analyses were conducted using CiteSpace, VOSviewer, and the bibliometrix R package. Indicators examined included publication trends, global distribution, institutional and author contributions, co-citation patterns, and keyword evolution. Results: Publications on exosomes in atherosclerosis have risen sharply since 2015, consistent with Price's Law. China contributes the largest volume, while the United States shows stronger international collaboration. Central South University, Capital Medical University, and Harvard University rank among the most productive institutions. Key contributors include Elena Aikawa and Lijun Yuan. Major publication venues are the International Journal of Molecular Sciences, Frontiers in Cardiovascular Medicine, and Frontiers in Immunology. Keyword and co-citation mapping revealed three major research axes: RNA-mediated regulation, immune and endothelial interactions, and emerging translational applications such as engineered exosomes and diagnostic biomarkers. Conclusion: This bibliometric analysis characterizes global research development and shows a shift from descriptive studies toward mechanistic insight and translational innovation. These trends may facilitate future efforts in biomarker discovery, standardized exosome workflows, and therapeutic development.
- Open Access
- 24 November 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1746339
Correction: Non-coding RNAs in heart failure: epigenetic regulatory mechanisms and therapeutic potential
There was a mistake in Figure 4 as published. In Figure 4, the word "faiure" was incorrectly spelled. The correct spelling is "failure." The corrected Figure 4 appears below.There was a mistake in Figure 5 as published. In Figure 5, the words "faiure" and "diabete" were incorrectly spelled. The correct spellings are "failure" and "diabetes," respectively. The corrected Figure 5 appears below.The original version of this article has been updated.
- 24 November 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1746339
Open AccessCorrection: Non-coding RNAs in heart failure: epigenetic regulatory mechanisms and therapeutic potential
There was a mistake in Figure 4 as published. In Figure 4, the word "faiure" was incorrectly spelled. The correct spelling is "failure." The corrected Figure 4 appears below.There was a mistake in Figure 5 as published. In Figure 5, the words "faiure" and "diabete" were incorrectly spelled. The correct spellings are "failure" and "diabetes," respectively. The corrected Figure 5 appears below.The original version of this article has been updated.
- Open Access
- 6 November 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1677797
Non-coding RNAs in heart failure: epigenetic regulatory mechanisms and therapeutic potential
Heart failure represents the terminal stage of diverse cardiovascular disorders and continues to impose a heavy global burden despite advances in therapy. Beyond classical neurohormonal and hemodynamic pathways, recent studies underscore the central role of non-coding RNAs in orchestrating epigenetic remodeling that drives hypertrophy, fibrosis, and cardiomyopathy. In this review, we synthesize evidence into an integrative “ncRNAs–epigenetics–cardiomyopathy” working model that connects upstream non-coding RNAs regulation with chromatin dynamics and downstream pathological remodeling. We integrate evidence showing how microRNAs, long non-coding RNAs, and circular RNAs reshape transcriptional networks through interactions with DNA methylation, histone, and RNA modifications. Differential non-coding RNAs signatures across heart failure phenotypes, comorbidities, and complications are further highlighted, underscoring their potential utility in patient stratification and biomarker discovery. We also evaluate therapeutic frontiers that extend beyond single-target interventions toward multi-layered approaches, including antisense oligonucleotides, CRISPR/dCas9-mediated epigenome editing, and exosome- or nanoparticle-based delivery systems. Although translational barriers remain considerable, especially in terms of specificity, safety, and clinical validation, these strategies illustrate the potential of targeting the ncRNAs–epigenetic axis to advance precision medicine in heart failure.
- 6 November 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1677797
Open AccessNon-coding RNAs in heart failure: epigenetic regulatory mechanisms and therapeutic potential
Heart failure represents the terminal stage of diverse cardiovascular disorders and continues to impose a heavy global burden despite advances in therapy. Beyond classical neurohormonal and hemodynamic pathways, recent studies underscore the central role of non-coding RNAs in orchestrating epigenetic remodeling that drives hypertrophy, fibrosis, and cardiomyopathy. In this review, we synthesize evidence into an integrative “ncRNAs–epigenetics–cardiomyopathy” working model that connects upstream non-coding RNAs regulation with chromatin dynamics and downstream pathological remodeling. We integrate evidence showing how microRNAs, long non-coding RNAs, and circular RNAs reshape transcriptional networks through interactions with DNA methylation, histone, and RNA modifications. Differential non-coding RNAs signatures across heart failure phenotypes, comorbidities, and complications are further highlighted, underscoring their potential utility in patient stratification and biomarker discovery. We also evaluate therapeutic frontiers that extend beyond single-target interventions toward multi-layered approaches, including antisense oligonucleotides, CRISPR/dCas9-mediated epigenome editing, and exosome- or nanoparticle-based delivery systems. Although translational barriers remain considerable, especially in terms of specificity, safety, and clinical validation, these strategies illustrate the potential of targeting the ncRNAs–epigenetic axis to advance precision medicine in heart failure.
- Open Access
- 17 October 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1636810
Empagliflozin’s cardioenergetic protective effects through PPARα pathway modulation in heart failure
Background: Heart failure (HF) pathology is complex and seriously life-threatening. SGLT2 inhibitors, as one of the new quadruple drugs for HF treatment, have a complex mechanism for improving HF. Energy metabolism is one of the important aspects of HF pathology, and the PPARα signaling pathway plays an important role in energy metabolism. Therefore, this study aims to observe changes in the PPARα signal transduction pathway in chronic HF by 18F-FDG MicroPET/CT imaging. Based on the myocardial metabolic imaging of 18F-FDG MicroPET/CT, this study aims to verify the mechanism of SGLT2 inhibitor treatment in rats with HF through the PPARα signal transduction pathway of energy metabolism and provide an imaging diagnostic basis.Results: In 18F-FDG PET/CT myocardial metabolic imaging, pretreatment myocardial glucose metabolism rate (MRGlu) levels in the HC group of HF rats were significantly higher than that in the other three groups. Post-treatment, MRGlu and glucose uptake decreased markedly in the empagliflozin (EMPG) group, while no significant changes were observed in the fenofibrate (FF) group. Compared with normal healthy rats, HF model rats showed a significant increase in MRGlu, and the expression of the lipid metabolism pathway proteins (PPARα, RXRα, CPT1α, and CD36) and the energy metabolism pathway proteins (AMPKα and sirt1) were significantly inhibited, while the expression of the glycolytic pathway protein (GLUT4) was enhanced. After 4 weeks of drug treatment in HF model rats, EMPG showed the same lipid metabolism pathway proteins (PPARα, RXRα, and CPT1α) and energy metabolism pathway proteins (AMPKα and sirt1) as FF, but only EMPG showed a significant decrease in MRGlu, inhibition of glycolytic pathway protein (GLUT 4) expression, and decreased cardiac fibrosis in HF rats.Conclusion: This study led to the following conclusions. 1) Rats with HF showed a significant increase in MRGlu compared with healthy rats. 2) Empagliflozin can improve the energy supply efficiency of the heart in rats with chronic HF by inhibiting glucose metabolism and promoting lipid metabolism, thereby ameliorating energy metabolism in chronic HF. 3) 18F-FDG MicroPET/CT can observe the energy metabolism changes of HF, and the MRGlu can provide quantitative data for the changes of HF energy metabolism.
- 17 October 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1636810
Open AccessEmpagliflozin’s cardioenergetic protective effects through PPARα pathway modulation in heart failure
Background: Heart failure (HF) pathology is complex and seriously life-threatening. SGLT2 inhibitors, as one of the new quadruple drugs for HF treatment, have a complex mechanism for improving HF. Energy metabolism is one of the important aspects of HF pathology, and the PPARα signaling pathway plays an important role in energy metabolism. Therefore, this study aims to observe changes in the PPARα signal transduction pathway in chronic HF by 18F-FDG MicroPET/CT imaging. Based on the myocardial metabolic imaging of 18F-FDG MicroPET/CT, this study aims to verify the mechanism of SGLT2 inhibitor treatment in rats with HF through the PPARα signal transduction pathway of energy metabolism and provide an imaging diagnostic basis.Results: In 18F-FDG PET/CT myocardial metabolic imaging, pretreatment myocardial glucose metabolism rate (MRGlu) levels in the HC group of HF rats were significantly higher than that in the other three groups. Post-treatment, MRGlu and glucose uptake decreased markedly in the empagliflozin (EMPG) group, while no significant changes were observed in the fenofibrate (FF) group. Compared with normal healthy rats, HF model rats showed a significant increase in MRGlu, and the expression of the lipid metabolism pathway proteins (PPARα, RXRα, CPT1α, and CD36) and the energy metabolism pathway proteins (AMPKα and sirt1) were significantly inhibited, while the expression of the glycolytic pathway protein (GLUT4) was enhanced. After 4 weeks of drug treatment in HF model rats, EMPG showed the same lipid metabolism pathway proteins (PPARα, RXRα, and CPT1α) and energy metabolism pathway proteins (AMPKα and sirt1) as FF, but only EMPG showed a significant decrease in MRGlu, inhibition of glycolytic pathway protein (GLUT 4) expression, and decreased cardiac fibrosis in HF rats.Conclusion: This study led to the following conclusions. 1) Rats with HF showed a significant increase in MRGlu compared with healthy rats. 2) Empagliflozin can improve the energy supply efficiency of the heart in rats with chronic HF by inhibiting glucose metabolism and promoting lipid metabolism, thereby ameliorating energy metabolism in chronic HF. 3) 18F-FDG MicroPET/CT can observe the energy metabolism changes of HF, and the MRGlu can provide quantitative data for the changes of HF energy metabolism.
- Open Access
- 24 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Association between C-reactive protein-triglyceride glucose index and Future cardiovascular disease risk in a population with cardiovascular-Kidney-metabolic syndrome stage 0–3
Cardiovascular–Kidney–Metabolic (CKM) syndrome, a concept recently introduced by the American Heart Association (AHA), emphasizes the intricate relationships among metabolic, renal, and cardiovascular diseases. The C-reactive protein–triglyceride–glucose index (CTI) has been proposed as an effective biomarker for insulin resistance (IR) and inflammation. Although there is substantial evidence demonstrating an association between the CTI and cardiovascular disease (CVD), its precise role in individuals with CKM syndrome stage 0–3 remains unclear. This prospective cohort study analysed data from China Health and Retirement Longitudinal Study (CHARLS), with a follow-up period of 10 years. The exposure variable was CTI at baseline, which was calculated as a combination of triglyceride (TG), fasting blood glucose (FBG), and C-reactive protein (CRP). The primary endpoint was the CVD. Cox proportional hazards regression and restricted cubic spline (RCS) analysis were conducted to examine the association between CTI and CVD risk. This study included 7,711 participants (52.38% female; mean age, 59.01 ± 9.37 years). An elevated CTI was significantly associated with a greater risk of developing CVD. Specifically, after fully adjusting for potential confounders, each one-unit increase in the CTI was associated with a 16% increase in CVD risk (hazard ratio [HR] = 1.16; 95% confidence interval [CI]: 1.06–1.27). Compared with participants in the lowest CTI group, those in the highest CTI group had a 42% greater CVD risk (HR = 1.42; 95% CI: 1.20–1.68). RCS analysis revealed a nonlinear association between CTI and the CVD risk among individuals with CKM syndrome stage 0–3 (overall P < 0.001; nonlinearity P = 0.01). This study revealed a positive association between CTI and CVD risk among individuals with CKM syndrome stages 0–3, suggesting that CTI may serve as a practical tool for CVD risk stratification in this population.
- 24 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Open AccessAssociation between C-reactive protein-triglyceride glucose index and Future cardiovascular disease risk in a population with cardiovascular-Kidney-metabolic syndrome stage 0–3
Cardiovascular–Kidney–Metabolic (CKM) syndrome, a concept recently introduced by the American Heart Association (AHA), emphasizes the intricate relationships among metabolic, renal, and cardiovascular diseases. The C-reactive protein–triglyceride–glucose index (CTI) has been proposed as an effective biomarker for insulin resistance (IR) and inflammation. Although there is substantial evidence demonstrating an association between the CTI and cardiovascular disease (CVD), its precise role in individuals with CKM syndrome stage 0–3 remains unclear. This prospective cohort study analysed data from China Health and Retirement Longitudinal Study (CHARLS), with a follow-up period of 10 years. The exposure variable was CTI at baseline, which was calculated as a combination of triglyceride (TG), fasting blood glucose (FBG), and C-reactive protein (CRP). The primary endpoint was the CVD. Cox proportional hazards regression and restricted cubic spline (RCS) analysis were conducted to examine the association between CTI and CVD risk. This study included 7,711 participants (52.38% female; mean age, 59.01 ± 9.37 years). An elevated CTI was significantly associated with a greater risk of developing CVD. Specifically, after fully adjusting for potential confounders, each one-unit increase in the CTI was associated with a 16% increase in CVD risk (hazard ratio [HR] = 1.16; 95% confidence interval [CI]: 1.06–1.27). Compared with participants in the lowest CTI group, those in the highest CTI group had a 42% greater CVD risk (HR = 1.42; 95% CI: 1.20–1.68). RCS analysis revealed a nonlinear association between CTI and the CVD risk among individuals with CKM syndrome stage 0–3 (overall P < 0.001; nonlinearity P = 0.01). This study revealed a positive association between CTI and CVD risk among individuals with CKM syndrome stages 0–3, suggesting that CTI may serve as a practical tool for CVD risk stratification in this population.
- 20 July 2023
- Published by Springer Nature in Apoptosis
- Vol. 28 (9-10) , 1496-1499
Correction: Angiotensin-(1–9) prevents Angiotensin II-induced endothelial apoptosis through CNPY2/PERK pathway
- 20 July 2023
- Published by Springer Nature in Apoptosis
- Vol. 28 (9-10) , 1496-1499
Correction: Angiotensin-(1–9) prevents Angiotensin II-induced endothelial apoptosis through CNPY2/PERK pathway
- Open Access
- 27 June 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Bioinformatics analysis and reveal potential crosstalk genetic and immune relationships between atherosclerosis and periodontitis
Periodontitis is an inflammatory and immune-related disease with links to several systemic diseases, and the pathological process of atherosclerosis also involves inflammatory and immune involvement. The aim of this study was to investigate the common immune cells and potential crosstalk genes between periodontitis (PD) and atherosclerosis (AS). By analyzing the weighted gene co-expression network of differentially immune infiltrating cells in two diseases to obtain important module genes, and taking the intersection of the module genes, we obtained 14 co-expressed immune-related genes, and evaluated the predictive value of 14 immune-related genes using three machine learning models.Two potential immune-related crosstalk genes (BTK and ITGAL) were finally obtained by taking intersections of WGCNA intersection genes, DEGs and IRGs.Then, the diagnostic column line graphs were constructed based on the 2 crosstalk genes, and the calibration curves, DCA curves and clinical impact curves indicated that the two genes had strong disease prediction ability, and we further validated the accuracy of the two potential crosstalk genes for disease diagnosis in the validation dataset.Single gene GSEA analysis showed that both genes are jointly involved in biological processes such as antigen presentation and immune regulation, and single sample GSEA analysis showed that macrophages and T cells play an important role in periodontitis in atherosclerosis.This study explored the genetic correlation between atherosclerosis and periodontitis using bioinformatics tools. BTK and ITGAL were found to be the most important crosstalk genes between the two diseases and may have an important role in the diagnosis and treatment of the diseases. Macrophage and T cell mediated inflammatory and immune responses may play an important role in periodontitis and atherosclerosis.
- 27 June 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Open AccessBioinformatics analysis and reveal potential crosstalk genetic and immune relationships between atherosclerosis and periodontitis
Periodontitis is an inflammatory and immune-related disease with links to several systemic diseases, and the pathological process of atherosclerosis also involves inflammatory and immune involvement. The aim of this study was to investigate the common immune cells and potential crosstalk genes between periodontitis (PD) and atherosclerosis (AS). By analyzing the weighted gene co-expression network of differentially immune infiltrating cells in two diseases to obtain important module genes, and taking the intersection of the module genes, we obtained 14 co-expressed immune-related genes, and evaluated the predictive value of 14 immune-related genes using three machine learning models.Two potential immune-related crosstalk genes (BTK and ITGAL) were finally obtained by taking intersections of WGCNA intersection genes, DEGs and IRGs.Then, the diagnostic column line graphs were constructed based on the 2 crosstalk genes, and the calibration curves, DCA curves and clinical impact curves indicated that the two genes had strong disease prediction ability, and we further validated the accuracy of the two potential crosstalk genes for disease diagnosis in the validation dataset.Single gene GSEA analysis showed that both genes are jointly involved in biological processes such as antigen presentation and immune regulation, and single sample GSEA analysis showed that macrophages and T cells play an important role in periodontitis in atherosclerosis.This study explored the genetic correlation between atherosclerosis and periodontitis using bioinformatics tools. BTK and ITGAL were found to be the most important crosstalk genes between the two diseases and may have an important role in the diagnosis and treatment of the diseases. Macrophage and T cell mediated inflammatory and immune responses may play an important role in periodontitis and atherosclerosis.
- Open Access
- 19 June 2023
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 25 (7) , 587-590
Aprocitentan: A new development of resistant hypertension
As the blood pressure threshold for commencing antihypertensive treatment diminishes, the cohort suffering from resistant hypertension (RH) correspondingly expands. Notwithstanding the availability of known antihypertensive medications, there exists a conspicuous lacuna in therapeutic options specifically intended for the management of RH. Currently, aprocitentan is the sole endothelin receptor antagonist (ERA) under development for addressing this pressing clinical challenge. Aprocitentan (ACT‐132577), deriving its active form as a metabolite of macitentan, demonstrates oral potency as a dual endothelin (ET) receptor antagonist. This compound effectively obstructs the binding of endothelin‐1 (ET‐1) to both ETA and ETB receptors, exhibiting an inhibitory potency ratio of 1:16. Clinical investigation of aprocitentan has advanced to phase 3 trials, yielding promising preliminary outcomes.
- 19 June 2023
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 25 (7) , 587-590
Open AccessAprocitentan: A new development of resistant hypertension
As the blood pressure threshold for commencing antihypertensive treatment diminishes, the cohort suffering from resistant hypertension (RH) correspondingly expands. Notwithstanding the availability of known antihypertensive medications, there exists a conspicuous lacuna in therapeutic options specifically intended for the management of RH. Currently, aprocitentan is the sole endothelin receptor antagonist (ERA) under development for addressing this pressing clinical challenge. Aprocitentan (ACT‐132577), deriving its active form as a metabolite of macitentan, demonstrates oral potency as a dual endothelin (ET) receptor antagonist. This compound effectively obstructs the binding of endothelin‐1 (ET‐1) to both ETA and ETB receptors, exhibiting an inhibitory potency ratio of 1:16. Clinical investigation of aprocitentan has advanced to phase 3 trials, yielding promising preliminary outcomes.